These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36015104)

  • 1. Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis.
    Wang D; Ge L; Guo Z; Li Y; Zhu B; Wang W; Wei C; Li Q; Wang Z
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis.
    Hwang J; Yoon HM; Lee BH; Kim PH; Kim KW
    Neurology; 2022 Mar; 98(9):e938-e946. PubMed ID: 35017312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
    BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis.
    Han Y; Li B; Yu X; Liu J; Zhao W; Zhang D; Zhang J
    J Neurol; 2024 May; 271(5):2379-2389. PubMed ID: 38502338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
    Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J
    Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful utilization of topical trametinib for neurofibromatosis type I-associated plexiform neurofibroma.
    Melnikov L; Brichta L; Schloemer NJ
    Pediatr Dermatol; 2024; 41(6):1246-1247. PubMed ID: 39225256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.
    Habibi MA; Mirjani MS; Ahmadvand MH; Delbari P; Alasti O
    Eur J Clin Pharmacol; 2024 May; 80(5):639-656. PubMed ID: 38345637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis.
    Lei J; Liu Y; Fan Y
    Neurosurg Rev; 2024 Aug; 47(1):458. PubMed ID: 39172230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
    Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
    Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
    J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety profile of selumetinib in symptomatic inoperable plexiform neurofibromas.
    Sharawat IK; Panda PK; Sihag RK; Panda P; Dawman L
    J Neurosurg Sci; 2022 Dec; 66(6):501-510. PubMed ID: 35301838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and surgical treatments of scoliosis in neurofibromatosis type 1: a systemic review and meta-analysis.
    Wang D; Zhang BH; Wen X; Chen KH; Xiao HT; Xu XW; Li QF
    Eur Spine J; 2024 Jul; 33(7):2646-2665. PubMed ID: 38526628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of trametinib on the neuropsychological profile of NF1 patients.
    Lalancette E; Cantin É; Routhier MÈ; Mailloux C; Bertrand MC; Kiaei DS; Larouche V; Tabori U; Hawkins C; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; McKeown T; Ospina LH; Vairy S; Ramaswamy V; Coltin H; Sultan S; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Caru M; Dehaes M; Jabado N; Perreault S; Lippé S
    J Neurooncol; 2024 May; 167(3):447-454. PubMed ID: 38443693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laser treatment for Cafe-au-lait Macules: a systematic review and meta-analysis.
    Guo ZZ; Wang ZC; Wang D; Ge LL; Li YH; Gu YH; Wang W; Wei CJ; Gu B; Yao M; Dong JY; Li QF
    Eur J Med Res; 2023 Jun; 28(1):185. PubMed ID: 37291616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
    Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
    ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
    Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
    Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1:
    Tritto V; Ferrari L; Esposito S; Zuccotti P; Bianchessi D; Natacci F; Saletti V; Eoli M; Riva P
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31694342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and disease severity in patients with mosaic neurofibromatosis type 1: a single-center study and literature review.
    Ejerskov C; Raundahl M; Gregersen PA; Handrup MM
    Orphanet J Rare Dis; 2021 Apr; 16(1):180. PubMed ID: 33853649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.